(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 January 2024 (18.01.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/015611 A3

(51) International Patent Classification:
A61K 39/39 (2006.01) *A61P 25/28* (2006.01)
A61K 38/16 (2006.01) *C07K 19/00* (2006.01)
A61K 38/17 (2006.01) *C07K 7/06* (2006.01)
A61K 47/02 (2006.01) *C07K 7/08* (2006.01)
A61K 47/26 (2006.01)

(21) International Application Number:
PCT/US2023/027832

(22) International Filing Date:
14 July 2023 (14.07.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/389,241 14 July 2022 (14.07.2022) US
63/393,533 29 July 2022 (29.07.2022) US

(71) Applicant: **VAXXINITY, INC.** [US/US]; 505 Odyssey Way, Merritt Island, FL 32953 (US).

(72) Inventors: **BOYD, Justin**; C/o Vaxxinity, Inc., 505 Odyssey Way, Merritt Island, FL 32953 (US). **DODART, Jean-Cosme**; C/o Vaxxinity, Inc., 505 Odyssey Way, Merritt Island, FL 32953 (US).


(74) Agent: **HALSTEAD, David P.** et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: TAU PEPTIDE IMMUNOGEN CONSTRUCTS

Fig. 1



(57) Abstract: The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Tau protein for the treatment and/or prevention of tauopathies. The present disclosure is also directed to compositions containing the peptide immunogen constructs, methods of making and using the peptide immunogen constructs, and antibodies produced by the peptide immunogen constructs.

[Continued on next page]

WO 2024/015611 A3

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
11 April 2024 (11.04.2024)